申请人:Japan Tobacco Inc.
公开号:US05354758A1
公开(公告)日:1994-10-11
Compounds of the formula I ##STR1## are disclosed. In this formula, R is a member selected from the group consisting of --CR.sub.1 R.sub.2 R.sub.3, hydroxy, an alkoxy group having 1 to 4 carbon atoms and --NR.sub.4 R.sub.5, in which at most one of R.sub.1, R.sub.2 and R.sub.3 is hydrogen and the remainder are each independently selected from the group consisting of an alkyl group having 1 to 4 carbon atoms, an alkenyl group having 2 to 4 carbon atoms, an alkynyl group having 2 to 4 carbon atoms, a cycloalkyl group having 3 to 7 carbon atoms, a cycloalkylalkyl having 4 to 9 carbon atoms and a 3 to 6 membered cyclic ether; R.sub.4 and R.sub.5 are each independently hydrogen or an alkyl group having 1 to 4 carbon atoms; R.sub.6 and R.sub.7 are each independently hydrogen or an alkyl group having 1 to 4 carbon atoms; and R.sub.8 is hydrogen, an alkyl group having 1 to 4 carbon atoms, hydroxy, an alkoxy group having 1 to 4 carbon atoms or halogen. Salts of these compounds are also disclosed. Also disclosed are pharmaceutical compositions of these compounds with a pharmaceutically acceptable carrier, the use of these materials as N-methyl-D-aspartate receptor antagonists, processes for preparing these compounds and salts, and methods to treat cerebral diseases by administering an effective amount of these compounds, salts or compositions.
公开了式I的化合物##STR1##。在这个公式中,R是从--CR.sub.1 R.sub.2 R.sub.3、羟基、具有1到4个碳原子的烷氧基团和--NR.sub.4 R.sub.5组成的群体中选择的成员,其中R.sub.1、R.sub.2和R.sub.3中最多有一个是氢,其余各自独立地选择自具有1到4个碳原子的烷基团、具有2到4个碳原子的烯基团、具有2到4个碳原子的炔基团、具有3到7个碳原子的环烷基团、具有4到9个碳原子的环烷基基团和具有3到6个成员的环醚的群体中;R.sub.4和R.sub.5各自独立地是氢或具有1到4个碳原子的烷基团;R.sub.6和R.sub.7各自独立地是氢或具有1到4个碳原子的烷基团;R.sub.8是氢、具有1到4个碳原子的烷基团、羟基、具有1到4个碳原子的烷氧基团或卤素。还公开了这些化合物的盐。还公开了这些化合物与药学上可接受的载体的药物组合物,以及将这些材料用作N-甲基-D-天冬氨酸受体拮抗剂,制备这些化合物和盐的方法,以及通过给予这些化合物、盐或组合物的有效量来治疗脑部疾病的方法。